← Back to Search

Behavioral Intervention

Safer Insulin Management for Older Adults with Type 2 Diabetes (SAGE Trial)

N/A

Recruiting

Led By Richard W Grant, MD MPH

Research Sponsored by Kaiser Permanente

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 75 years and older

Current treatment with insulin

Must not have

Severe Visual Impairment

Dementia

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 and 12 months after study start date

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to test a new approach for prescribing insulin to older adults with type 2 diabetes who are at high risk for severe hypoglycemia. The approach involves using continuous glucose monitoring and

Who is the study for?

This trial is for older adults aged 75 and above with type 2 diabetes who are currently on insulin treatment. Participants should have experienced low blood sugar in the past year, be able to communicate in English, and have access to email and the Internet.

What is being tested?

The study tests a new educational program using continuous glucose monitoring to help prevent severe low blood sugar episodes. Participants will either attend SAGE group sessions, combine these sessions with support from a diabetes pharmacist, or receive usual care without additional education.

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort at sensor sites for glucose monitoring and possible anxiety or stress from continuous health tracking. Usual care likely has no additional side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 75 years old or older.

Select...

I am currently being treated with insulin.

Select...

I have been diagnosed with Type 2 Diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have severe difficulty seeing.

Select...

I have been diagnosed with dementia.

Select...

I am currently on kidney dialysis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 and 12 months after study start date

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 and 12 months after study start date

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 and 12 months after study start date for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hypoglycemia aggregate outcome

Secondary study objectives

Diabetes Distress

Hypoglycemia Confidence

Hypoglycemia Distress

+2 more

Other study objectives

Caregiver Action

Confidence in Adjusting Insulin

Insulin Adjustment

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group Education SessionsExperimental Treatment1 Intervention

Participants will participate in 3 educational sessions designed to teach about applying and using continuous glucose monitors \[CGMs\] (Session 1) and how to prevent hypoglycemia episodes based on CGM readings and hypoglycemia journal entries (Sessions 2 \& 3).

Group II: Usual CareActive Control1 Intervention

Participants allocated to the control arm will continue with usual care.

0 / 6Eligibility criteria met